Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SSTR4 | P31391 | 11/20 | 0.48 |
| ▸ | SSTR3 | P32745 | 8/20 | 0.48 |
| ▸ | SSTR2 | P30874 | 5/20 | 0.48 |
| ▸ | SSTR1 | P30872 | 5/20 | 0.48 |
| ▸ | PGR | P06401 | 4/20 | 0.46 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | FNTA | P49354 | 1/20 | 0.41 |
| ▸ | FNTB | P49356 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6976722 | 0.85 | PGR (0.44) | SSTR4SSTR3SSTR1PGRMAPT | |
| SCHEMBL6983331 | 0.83 | SSTR4 (0.47) | SSTR4SSTR3SSTR2SSTR1PGR | |
| SCHEMBL6981611 | 0.80 | PGR (0.49) | PGRMAPT | |
| SCHEMBL6981373 | 0.79 | SSTR4 (0.50) | SSTR4SSTR3SSTR2SSTR1MAPT | |
| SCHEMBL6981339 | 0.77 | CYP11B1 (0.49) | PGRMAPT | |
| SCHEMBL6981838 | 0.77 | PGR (0.52) | PGRMAPTFNTAFNTB | |
| SCHEMBL6981436 | 0.75 | CYP1A2 (0.51) | PGR | |
| SCHEMBL6982038 | 0.75 | PGR (0.52) | PGRMAPTFNTA | |
| SCHEMBL6980468 | 0.74 | TP53 (0.46) | PGRMAPT | |
| SCHEMBL6980685 | 0.72 | PGR (0.56) | PGRMAPTFNTAFNTB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030199530-A1 | New compounds derived from quinazoline | LES LABORATORIES SERVIER (FR) | 2003-10-23 | — | — | US | disclosed |
| EP-1346992-A1 | Quinazoline derivatives, process for their preparation and pharmaceutical compositions containing them | Les Laboratoires Servier (FR) | 2003-09-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030199530-A1 | New compounds derived from quinazoline | NQO2, XDH, DRD1 | SSTR4 4554/4885SSTR3 4431/4885SSTR2 3817/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.